surmount-osa trial tirzepatide results findings demonstrate benefit of in treatment of obesity-related OSA SURMOUNT-OSA: 4 in 10 Who

Given the established clinical use of GLP-1RAs for the treatment of T2DM, preclinical and clinical research was centered largely around DR, which suggested the neuropathologic protective effects of GLP-1 are due to downregulation of NF-B, proinflammatory cytokines such as TNF-alpha and IL-1beta, and VEGF

For individuals with obesity or those at risk of developing type 2 diabetes, GLP-1 injections offer a proven option to help manage weight and improve overall health

SNRIs (serotonin-norepinephrine reuptake inhibitors) such as venlafaxine and duloxetine similarly do not interact with tirzepatide at the metabolic level

As a series